

Summary Attachment

Date: July 16, 2021

Protocol Title: A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients with Stable Sickle Cell Disease

Protocol Number: C1701-202

Product: Olinciguat (IW-1701)

EudraCT Number: 2019-001899-11

Sponsor: Cyclerion Therapeutics, Inc.

Global End of Trial/ Early Termination in the UK (EU): 06-Aug-2020

Per study protocol C1701-202, the last adjudication of vaso-occlusive crisis events (VOC) defined the end of the study which was performed on 06-Aug-2020. Global end of trial / Early termination in the UK (EU) notification was submitted to Medicines and Healthcare products Regulatory Agency (MHRA) on 08-Oct-2020.

In this study, subjects were randomized at 25 study centers in the United States (US) and at 2 study centers in Lebanon. The UK was the only country in Europe where a clinical trial application (CTA) was submitted, however global enrolment had closed before any subjects were randomized at any UK sites. Therefore, the Sponsor herewith submits a summary attachment to inform that no subjects were recruited for Study C1701-202 in the UK and no results are available in UK subjects.

Reema Bhatt
Sr. Manager, Global Regulatory Affairs
Cyclerion Therapeutics, Inc.

tel: (857) 338-3358
fax: (617) 902-2573
e-mail: rbhatt@cyclerion.com